Evidence-based articles on biohacking, AI research and substances — anchored in real scientific studies.
For GHK-Cu, there is a high-quality RCT in skincare for a topical copper-peptide complex after CO₂-laser resurfacing (Miller 2006). For many “anti-aging” claims, however, there are usually no direct clinical endpoints. Studies on permeation, formulations, and mechanisms are mostly laboratory or ex-vivo data.
Hydration is partly supported by studies, but the direct, high-quality evidence overall is limited. In a sports context, there are indications that carbohydrate-electrolyte solutions can influence recovery after exertion. For general health, many statements are currently not sufficiently proven.
Hormonal contraception works by hormonally regulating reproductive processes; the strongest evidence comes from randomized studies (e.g., mechanisms of action in male formulations). Many safety questions have been investigated using registry and observational data, sometimes with limited causal inference. The article categorizes study quality, benefits vs. risks, and remaining evidence gaps.
The evidence for “breakfast yes or no” is inconsistent. For metabolic parameters there are individual RCTs (e.g., in type-2 diabetes using early-day carbohydrate training limits plus a protein-rich breakfast). Effects on cognition, inflammation, and sleep are currently limited to small studies or supported only indirectly. Lifestyle levers like sleep, daylight, and meal timing often matter more overall.
Salt, i.e., sodium, affects blood pressure and therefore cardiovascular risks—especially in people with hypertension. For many aspects, however, the evidence is nuanced: meta-analyses suggest benefits of lower sodium intake for specific endpoints, while extreme intakes and special populations require additional caution.
Topical peptides are a heterogeneous field: for efficacy in skin issues, clinical data is still limited, including a small RCT on TCP-25 gel in wounds with a safety-focused endpoint. Many commonly discussed applications rely more on reviews, single studies, or preclinical research.
Blue light filters are best supported by an RCT in schoolchildren: they shifted the sleep phase earlier and improved daytime behavior, without changing nocturnal salivary melatonin secretion. For adults, the evidence is mainly observational. For vision/technology questions, there are smaller studies on color perception and image/task performance.
In men with diagnosed hypogonadism, TRT can improve certain symptoms, but it’s not proven for everyone. Several updated meta-analyses of randomized studies are available for safety, though they come with important caveats regarding study duration and patient selection. The key factors are diagnosis, target levels, monitoring, and risk-benefit decisions—not a “Testo for all” approach.
Movement can support learning and skill acquisition, especially when the training is tailored to the specific task. However, the evidence base is limited: effects for “general learning” aren’t reliably demonstrated. Good practice: prioritize moved task training, sufficient (but recovery-friendly) intensity, sleep, and recovery. Supplements only if you have a real need signal.
The gut–brain axis is plausible, but human evidence is heterogeneous: One RCT shows effects of Lacticaseibacillus paracasei on sleep duration, and meta-analyses link the microbiome with depression. For many popular claims, hard RCT data are missing. Lifestyle levers like movement and diet remain the foundation.
For WADA/doping, the focus is not the “effects” but the detection of prohibited substances. The strongest available evidence here is an RCT on cannabidiol showing measurable urine concentrations after daily use and exercise. For other substance classes, the data are primarily analytical methods, reviews, and supplement adulteration.
DEXA measures bone density as a proxy for osteoporosis risk, but it’s not the risk itself. For postmenopausal women, multiple meta-analyses suggest that training can preserve/improve bone density—stronger when intensity and loading type are a good match. Because DEXA results are an indirect endpoint, clinical fracture data are often limited.
Good posture is not automatically “healthier,” but certain body positions can change measurable physiological responses and may improve behavior short-term through feedback systems. The strongest evidence relates to effects in the context of loading and ergonomics; for long-term pain relief, data overall remain limited. Choose evidence over intuition.
tDCS is a non-invasive brain stimulation technique, and the evidence base varies strongly by target area. There are individual RCTs and one meta-analysis on cognitive function, but there is no consistent evidence of effectiveness across all applications. Lifestyle levers like sleep, movement, and training usually have more robust evidence than tDCS single interventions.
The lipid profile (LDL-C, HDL-C, triglycerides, sometimes remnant cholesterol) is well measurable, but not every claimed “effect” of individual interventions is supported equally well. For lifestyle and treatment levers, the evidence varies by each endpoint. Available RCT data for supplements is limited.
A morning routine isn’t simply “effective” or “ineffective.” There are individual RCTs or feasibility studies in specific patient groups (e.g., delir prevention), but there is little direct evidence for healthy people. Lifestyle levers like sleep, light, and structure are plausible and often better supported than supplements.
Leptin is linked to satiety and energy metabolism, but robust, specific claims about “improvement with leptin” are limited. For leptin levels, the dataset is anchored mainly by one high-quality lifestyle study (evidence B) addressing training/diet effects. Many additional findings come from animal mechanistic research.
Norepinephrin ist als Botenstoff zentral für Wachheit, Stressantwort und Gehirn-Netzwerke—aber stabile Aussagen zur „Supplement-Wirkung“ sind aus den vorhandenen Studien nicht direkt ableitbar. Zwei Meta-Analysen adressieren verwandte adrenerge Wirkmechanismen/Behandlungen; RCTs zu Norepinephrin als Substanz fehlen weitgehend. Lifestyle-Hebel wie Schlaf und Training sind der bessere Start.
Massage devices can influence certain measurements in the short term (e.g., flexibility or muscle-related sensations), but overall evidence is limited and often based on small studies and specific protocols. For pain, recovery, and trigger points there are some RCT-adjacent data, yet hard long-term endpoints are frequently missing. Priority: sleep, movement, and load management.
A “rebound” after stopping GLP‑1 is plausible, but the evidence is not consistent. For rapid remission, there are RCT hints in the diabetes context; for general rebound effects, robust data are lacking. The key is lifestyle levers and a structured follow-up plan.
Training stress is more than “too much training”: it affects stress regulation, mental resilience, and sometimes physical markers. In the current evidence base, there are some RCTs with credible effects (evidence level B), but much of the picture is still non-specific or heterogeneous. Lifestyle levers like sleep, load management, and recovery should come first.
Ipamorelin is a so-called growth-hormone secretagogue peptide. In human evidence, the core dataset is mainly one PK/PD study (a signal- and dose-response model) and one Proof-of-Concept RCT for postoperative ileus. Animal data suggest potential effects related to bone and hormone interactions, but these findings are not directly transferable to humans.
A sleep lab (polysomnography) measures sleep precisely and is especially relevant for diagnosis. For “effects” from interventions, high-quality RCTs are scarce—for example, yoga nidra in a laboratory setting. Wearables are promising, but the clinical equivalence to polysomnography is not yet reliably established with hard endpoint trials.
Homocysteine has been studied as a biomarker associated with cardiovascular risk, pregnancy complications, and some neurological topics. However, the best evidence for direct benefits from supplements is limited or inconsistent. Priority should go to lifestyle levers—diet, activity, and possibly clarifying B-vitamin status—rather than blindly substituting.
Zone-2 training is often described as an “aerobic base,” but the evidence base for clearly defined zone-2 intervals in high-quality studies is thin. A strong study typically offers only indirect insight via “training and adaptations.” Priority remains: determine your pulse and threshold parameters cleanly, and optimize sleep and overall movement first.
Placebo and nocebo can produce measurable effects through expectations, information, and negative treatment expectations. Stronger evidence comes from systematic reviews and selected RCTs, while effect sizes vary widely depending on context. Key point: Lifestyle and communication can meaningfully shift both risks and benefits.
The best available evidence for the claim that “testosterone boosters” increase serum total testosterone is currently limited: A systematic review finds no convincing, consistent effect across different products (Morgado et al., 2024). Lifestyle levers and targeted diagnostics are usually the more sensible route than buying supplements.
For endometriosis, the evidence base is heterogeneous: systematic reviews exist for diagnosis and quality of life. For many therapy approaches, the data are too limited or restricted to mechanistic and/or animal/lab findings. Lifestyle factors and evidence hierarchy should be prioritized over supplements.
Urolithin A is formed from gut metabolites or ellagitannins and is discussed as a possible mitophagy activator. In humans, there are safety and biomarker/signature data (Andreux 2019, PMID 32694802). For hard clinical endpoints, the data are currently limited and mostly derived from reviews and mechanistic work. Sleep and dosing assumptions are still not sufficiently substantiated.
Cancer screening can improve survival only if it finds the right cases early enough and demonstrably affects relevant endpoints. Evidence quality varies substantially by screening program. From the available sources, the main takeaway is that guideline and RCT evidence for prevention/treatment does not automatically transfer to screening.
Overtraining is not just “more training”: the evidence base is heterogeneous and often centers on athletes, markers such as HRV or biomarkers, and psychological outcomes. There is only limited—sometimes indirect—evidence for strong, universally applicable claims. Prioritize sleep, recovery, and load management over supplements.
For menopause symptoms, the evidence is nuanced: For the genitourinary menopausal syndrome, there is a current systematic review on Lactobacillus-based probiotics (Tsuboi 2026). For hot flashes, guideline review documents and real-world data exist for Fezolinetant (North American Menopause Society 2023, Hsu 2026). For many supplement combinations, effects are not sufficiently supported.
Overall, the evidence on protein timing is rather “moderate”: many effects, if present at all, are small and strongly depend on training status, protein type, and surrounding conditions. Systematic reviews evaluate timing alongside dose and protein type; for clear, universal timing advice, the data is not yet strong enough.
Smartphone addiction is associated with more sleep problems and stress-related factors, especially in cross-sectional and model studies in adolescents and university students. Robust cause-and-effect evidence from RCTs is currently missing. The most reliable lever remains lifestyle: reduce evening light/screen time, lower stress, and stabilize a sleep routine.
The blood-brain barrier regulates exchange between blood and brain, especially in inflammation, infections, and certain diseases. In the current evidence base, reviews/meta-analyses describe mechanisms and associations, but for “self-biohacking” there are no robust RCT data. Concrete risk factors and lifestyle levers like sleep, movement, and inflammation management come first.
Contraindications are only as good as the underlying studies. Systematic Reviews often support robust warning statements more reliably than isolated single reports. For individual agents, efficacy and safety must be considered separately, and lifestyle levers (e.g., sleep, nutrition, movement, light) are often the priority. The evidence quality varies widely.
„Dopamine detox“ is, as a concept, usually not clinically tested; there is no direct, high-quality study isolating a dopamine detox approach. The available evidence mainly supports that problematic media use is associated with sleep and mental health problems. A consistent media withdrawal period may be practically worthwhile.
Sunlight is best supported for effects on the circadian rhythm and, from that, downstream goals such as better sleep regulation. Large observational datasets link outdoor light with mood and sleep, but the causal proof is limited. There is no robust clinical evidence for “healing.”
Microplastics are studied in terms of environmental burden, measurement methods, and potential health risks. For robust effects in humans, the data are currently limited; many findings come from animal and exposure/mechanism studies. Use the evidence hierarchy: start with environmental reviews, then identify human gaps, then consider animal mechanism evidence.
Correlation only shows that two things occur together, but not why. Causation requires study designs that control for confounding—most strongly randomized controlled trials (RCTs) and the systematic reviews of them. Use the evidence hierarchy: check the population, endpoints, and bias risk, and prioritize lifestyle levers over supplement promises.
Hormone axes regulate hormones and their feedback loops (e.g., HPO/HPT/HPA), but clinically usable “modulation” is often poorly supported. This overview categorizes the available evidence (systematic reviews, mechanistic studies, reviews) and explains why lifestyle levers usually matter more than supplements.
Nature contact (“Nature Exposure”) is associated in studies with better mental health, sometimes less pain, and effects on attention and mood. The evidence varies: there are systematic reviews on pain and light/Nature mechanisms, but not every outcome is already secured by many RCTs. Lifestyle: Nature + movement + light first, before supplements.
Morning light can support your circadian rhythm and thereby improve the timing of sleep, morning alertness, and sometimes sleep quality—especially when timing and light intensity match. Studies show effects for delayed sleep phase disorder, depression, and daytime sleepiness after TBI. For precise dose recommendations, the evidence is heterogeneous.
For panic attacks, the strength of evidence varies across triggers and interventions: there are controlled studies for medications (e.g., sertraline/propranolol), while for caffeine there are targeted RCT data on acute anxiety responses. Many “trigger” claims are based instead on case reports, observational data, or safety databases—limiting how confidently you can interpret them.
Adrenaline and noradrenaline are central messengers of the sympathoadrenal system, but many popular claims about “optimization” are not directly demonstrated in human studies. From the available reviews and metabolism/training data, the main signal concerns roles in obesity, sarcopenia, and workload/stress responses—yet not a safe “supplement strategy.”
If the thyroid isn’t functioning correctly, it can affect energy, weight, and performance—but much outside the disorder is only indirectly linked or supported by limited data. For photobiomodulation, there is a systematic analysis of mechanisms/clinical applications (evidence is still somewhat unclear). For “therapy in non-thyroid topics,” effects in reviews are assessed. Lifestyle often has more impact than supplements.
“Adrenal Fatigue” is not established as a clearly defined diagnosis in scientific terms. However, there is relevant evidence for the stress axis, including in the context of ME/CFS (systematic review on cortisol signatures) and RCTs on stress/fatigue-relevant interventions such as Ashwagandha. For “Adrenal Fatigue” in the sense of a general wellness syndrome, data are limited.
The immune system is complex, and many claims come from specialized fields or reviews rather than clearly defined RCTs. The available evidence can often be limited to specific contexts (e.g., immune components in diseases, microbiome interactions). For everyday use, robust lifestyle levers are usually more evidence-backed than supplements.
Shift work is associated with sleep problems and health-related risks, supported by systematic reviews. For specific actions, the evidence is often indirect: lifestyle approaches (light, sleep timing/regularity, nutrition, exercise) should come first. Supplements such as melatonin have RCT data, but not for all endpoints.
Chronic stress is associated with various complaints, but the evidence base is inconsistent: there are indications from studies (including on pain, stress measurement, and tinnitus), yet often no strong causal proof. For practical improvements, sleep, movement, light, and stress-management are the most robustly supported foundation.
fT3 and fT4 are considered core lab markers of thyroid function, but their “direct effects” in daily life are often hard to prove causally. Systematic Reviews mainly show the usefulness and limitations of test strategies for low-value lab tests. Lifestyle levers (sleep, nutrition, inflammation) can indirectly shift the values—and also affect how they should be interpreted.
TSH is a lab marker, not a “bioactive ingredient.” For the question of how TSH changes in response to interventions, meta-analyses provide the strongest clues—often indirectly via thyroid function rather than TSH alone. For migraine, exercise, selenium, vitamin D, or TMS, the evidence strength varies by topic. Safety and dosing depend on the specific therapy.
Bruxism is common, but not everything is well supported. In a systematic review on clear aligners, there are indications, yet no consistent evidence for effectiveness. An RCT reports long-term results for ceramic crowns against nocturnal bruxism. Lifestyle levers such as sleep and stress remain central.
Sarcopenia is best addressed through lifestyle: consistent training and adequate protein intake are consistently linked with improvements in muscle mass and strength in meta-analyses. For many supplements, the data is less robust. The evidence base clearly distinguishes between meta-analyses and individual RCTs.
For mood and psychological symptoms, there is currently no robust “glucose-direction causal link” from a large body of RCTs. Two systematic reviews on bipolar disorder consider metabolic relationships; one RCT shows benefit of Continuous Glucose Monitoring in type-2 diabetes. Supplements for glucose control have been studied in parts, but specific mood effects are usually unclear.
Training frequency mainly works through total volume, recovery capacity, and the adaptation stimulus. In the available reviews (including those on interval training / sport-like small-sided games and resistance training in specific groups), there are signals—but not always direct “higher vs. lower” RCT evidence. The evidence base differs by goal and population.
So far, there is little direct, high-quality evidence on the specific effectiveness of Paleo. A scoping review on dietary patterns and mental health screens RCTs but does not yield clear Paleo-specific effects. Metabolomics and single-arm studies suggest associations, but they do not establish causality.
TB-500 (Thymosin-β4 fragment) has been studied in humans only to a limited extent. In RCTs, there are indications of improvements in specific indications such as venous ulcers and dry eye, alongside pharmacokinetic/safety data on Thymosin β4. For “performance” or “anti-aging,” the data is currently not robust enough to support reliable conclusions.
Supercompensation describes a time-limited “overcompensation” in performance or glycogen after an exercise bout, provided appropriate recovery follows. The strongest evidence usually concerns glycogen repletion and carbohydrate timing; broad “performance miracles” are not consistently proven. The data are context-dependent (training type, energy availability, and damage level) and often indirect.
Research examines nicotine as a cognitive-active compound via nicotinergic receptors, but the overall evidence for a convincing “nootropic effect” is limited. The most important added value is an honest look at the state of the studies, plausible mechanisms, and safety/tolerance issues—plus the priority of sleep, movement, and light over supplements.
Speed-strength (Speed-Strength) is trained mainly through ballistic or high-speed, resistance-based exercises; the study record in the provided list focuses on older or specialized populations. The strongest defensible basis comes from systematic reviews/meta-analyses. For supplements, evidence is often indirect and not equally “speed-strength-specific.”
Glucose and ketones measurably affect metabolic pathways in the body, but the evidence quality differs depending on your goal. A Systematic Review on exogenous ketosis suggests potential benefits for certain conditions. RCTs in recovery and sport show effects on glycemia/carbohydrate handling. Many everyday questions remain data-limited.
The parasympathetic nervous system is often measured indirectly via heart rate variability (HRV). The strongest evidence comes from systematic reviews on vagus nerve stimulation and HRV-related contexts (including, for example, mental health conditions and asthma). For broad “direct” health claims, the data is often limited and methodologically heterogeneous.
The strongest evidence on the health effects of air pollutants focuses mainly on indoor air from biomass smoke and an increased risk of COPD (meta-analysis). For schools, biomonitoring, and modeling, there are sometimes hints, but often no clean causal studies. In practice, lifestyle levers help first: reduce exposure, improve ventilation.
Sleep apnea is common and diagnostically and therapeutically demanding. For some non-drug approaches, meta-analyses exist—for example, oropharyngeal exercises/myofunctional therapy. For other topics, the evidence remains thin or indirect. We clarify evidence tiers, measurable endpoints, and what to watch for in real-world practice.
Sleep loss lowers testosterone in healthy men in experimental studies; a meta-analysis shows measurable changes with partial and total sleep deprivation. For melatonin or specific supplement strategies, the evidence is much thinner. Priority: improve sleep quality, treat sleep apnea, optimize lifestyle.
Effect size (Effect Size) tells you how large an observed benefit is relative to its variability. This article explains the evidence landscape: for many topics, you need multiple RCTs/meta-analyses to make robust claims. We grade the evidence and show which levers are more strongly supported by data—and where uncertainty remains.
Biohacking is targeted experimentation with lifestyle and biological interventions to improve health. The evidence base is highly heterogeneous: for many approaches, strong RCTs are missing; systematic reviews often highlight limits more than clear effects. Before trying supplements or high-tech, sleep, movement, and nutrition are usually the best evidence levers.
The best available evidence links daily screen use with poorer sleep in adolescents (meta-analysis). For adolescents/young adults, associations are plausible, but much of the evidence is observational. Concrete dose thresholds are not robustly established. Lifestyle levers—light, sleep routine, and screen “time-outs”—are the first choice.
Intra-Workout is well described as a concept, but the studies listed here primarily support other medical “intra” settings. For training effects in the sense of “Intra-Workout” (e.g., carbs/protein during exercise), the evidence is only indirect/related to closely adjacent questions. Lifestyle levers like sleep, movement, nutrition, and training programming remain the best approach.
Psychotherapy shows clinically relevant improvements in several RCTs, for example in PTSD and depressive disorders. For certain modern variants (e.g., role-play–based or spiritual approaches), the data are often heterogeneous or more focused on training/application. Consider lifestyle levers before supplements, but use psychotherapy in a targeted way.
SHBG (sex hormone–binding globulin) is a marker and potentially an active regulator of free androgen levels. However, for clear, direct SHBG effects from single interventions, study evidence is limited and heterogeneous. The article ranks the evidence hierarchy (meta-analyses, RCTs, Mendelian randomization) and critically discusses PCOS-proximal evidence.
Ultra-processed foods are linked in many observational studies to a higher risk of inflammation, metabolic, and cardiovascular problems. For hard endpoints, direct RCT evidence is sometimes missing; systematic reviews and mechanistic data offer indications. Start with dietary patterns, sleep, and physical activity as levers instead of supplements.
Cool-down (e.g., 5–10 minutes of easy jogging) is plausible for comfort and a gradual transition in cardiovascular load, but direct evidence for clear, large performance or recovery gains is limited. Results for cardiovascular and inflammatory markers vary. Prioritize sleep, movement in the right amount, and training without overreaching.
Cerebrolysin has mainly been studied in meta-analyses on vascular dementia, with indications of benefit on cognitive endpoints. For Alzheimer, the evidence is weaker and more heterogeneous. For acute stroke/neuroinflammatory mechanisms, additional systematic reviews exist, but concrete efficacy evidence remains limited. Lifestyle levers remain the foundation.
Periodization can improve strength and hypertrophy development compared with non-periodized or differently structured programs—but the size of the effects varies with the training design. Three systematic reviews/meta-analyses show differences mainly for volume-equated programs between linear and undulating patterns. What matters most are your goal, progression logic, training volume, and recovery.
“Bias” means systematic distortion in studies and in how results are analyzed. The evidence base varies substantially by topic: meta-analyses show more robust effects for bias-/precision methods and for several clinical questions, while other areas remain heterogeneous or indirect. Study design, endpoints, and statistical quality are crucial.
Fats act differently depending on type and overall diet. Hooper et al. (Cochrane) find no clear weight effect from total fat alone; Sun et al. (network meta-analysis) organizes dietary patterns for cardiovascular risk-factor profiles; Fridén et al. (RCT) tests fat macro- and quality reallocations for fatty liver. Evidence is clearer for risk factors than for broad claims about “general health.”
Low Carb can contribute to weight loss in overweight populations and may support remission in type-2 diabetes, according to meta-analyses. Effects vary by population (e.g., adults vs. children, trained athletes). For sports performance and hormones, the data are sometimes limited. For a conclusion, the quality of the specific evidence always matters.
Evidence on the digestive system is inconsistent: For irritable bowel syndrome, meta-analyses of probiotics/prebiotics show some benefits depending on the endpoint and the product. For digestive cancers and obesity, prospective data support risk associations. For perioperative oral carbohydrates, benefit exists as a perioperative measure. Many lifestyle levers (diet, movement, weight) matter more than supplements.
Cravings are most reliably influenced through behavior and context. Systematic evidence suggests that longer caloric restriction reduces cravings. Mindfulness-based interventions also reduce food-craving severity in controlled studies. But for “cravings” as a standalone target, important unanswered questions remain, depending on the subgroup.
For PCOS, the evidence for a few key levers is relatively strong: GLP-1 receptor agonists show measurable effects on weight and metabolic parameters in RCT meta-analyses, and supplements such as magnesium or melatonin have at least partial evidence. For many other supplements, the data is limited and heterogeneous. Lifestyle levers should come first.
Burnout prevention is best supported by workplace-focused interventions and protective factors in healthcare. For meditation/breathing there are early RCT data, but transferability is limited. Evidence varies strongly by occupation, measurement tools, and study design. This article ranks the evidence by strength—while emphasizing lifestyle levers over supplements.
Benzodiazepines work acutely sedating, but the evidence base for a reliable long-term benefit–risk trade-off is limited and strongly context-dependent. For sleep in special situations, there are individual RCTs and meta-analyses, yet many effects cannot be cleanly generalized. In addition, stop-and-reduction strategies and safety considerations are central.
Carbohydrates can work differently depending on context. For glucose/metabolic effects, outcomes depend strongly on which carbohydrate source was studied and on the specific study design. In the meta-analyses available, the most consistent themes relate to glycemic control through SCFAs, risks in dietary pattern contexts, and performance in endurance exercise.
For Hashimoto, many promises are hard to classify because of a lack of hard data. Three of the mentioned studies provide higher evidence: acupuncture/moxibustion (systematic), photobiomodulation (mechanisms & clinical evidence), and one RCT on eye movement desensitization and reprocessing (EMDR) approaches. For nutrition, GLP‑1, and the microbiome, the data is mostly mechanistic or preliminary.
Resting Pulse (Resting Heart Rate) is considered a marker of cardiovascular health, but the exact “improvement” depends on the intervention and how it was studied. In the available meta-analyses, effects are often indirectly supported via outcomes such as blood pressure, fitness, or heart rate variability. Lifestyle (sleep, endurance training, load management) remains the most important lever.
Free testosterone is biologically active, but the direct benefit—i.e., the “effects” on specific endpoints—is only partially well studied. The strongest evidence concerns measurement methods and associations (e.g., inflammation, lifestyle, weight loss). Systematic reviews of interventions more often show indirect effects. Supplements are not evidence-validated.
Lion’s Mane (Hericium erinaceus) has been tested on cognition, stress/mood, and partly depressive symptoms in RCTs and two Systematic Reviews. Some studies find measurable improvements, while other effects are inconsistent. For dosing and safety there are indications, but the data basis remains limited; lifestyle levers such as sleep and movement come first.
GLP-1 receptor agonists commonly cause mainly gastrointestinal side effects and also affect weight and blood sugar—this is well covered in reviews and meta-analyses. For rare events (e.g., Wernicke encephalopathy) the evidence mainly comes from case reports and pharmacovigilance. Data on hair loss and eating-behavior risks are limited and sometimes only summarized systematically.
Fisetin is discussed as a potential senolytic and/or for modulating cellular senescence in several systematic reviews. The available evidence is mostly preclinical or focuses on side topics along specific disease axes; robust human RCT data are still largely missing. Prioritize sleep, movement, and metabolic health as primary levers, and treat supplements as uncertain.
Dementia prevention isn’t solved with a single “active ingredient.” In RCTs, especially structured multidomain lifestyle programs show measurable effects on global cognition. Biomarker and supplement data are inconsistent and often not designed to test dementia endpoints. The strongest conclusions come from systematic reviews and meta-analyses.
IGF-1 is a growth and signaling hormone studied across multiple areas. The strongest data in your set come mainly from systematic reviews on early life phases (growth/metabolism) and on retinopathy of preterm infants. For Alzheimer’s, skin regeneration, and CP improvements, the evidence quality so far is different—so the key is to interpret study strength correctly.
Depending on your goal, protein has different evidence levels. For general dietary and risk-factor questions, the strongest signals come from patterns of eating studied in context—not from “protein alone.” For many questions, direct protein RCT evidence is missing; the available data is sometimes indirect via metabolism, inflammation, and lifestyle pathways.
For the cardiovascular system, some effects are well supported, others only indirectly or remain uncertain. In older patients with coronary heart disease, intensive statin therapy shows benefits in a meta-analysis. GLP-1 agonists improve body weight in obesity/OSA, which can plausibly affect heart risks. For HRV in menopause and processed meat, the data has been systematically reviewed—but the strength of evidence varies.
Training volume mainly works through muscle hypertrophy and strength, but the benefit usually follows a “more is better up to a point” logic. The best evidence comes from systematic reviews and meta-analyses. For concrete target values, hard dose data is often missing—so progression, recovery, and your goal (strength vs. endurance) matter most.
Pregnenolone has been studied in several small RCTs for specific indications (including alcohol dependence, cocaine dependence, chronic low back pain, and irritability in autism). Overall, the data are limited: there are signals of measurable effects in certain settings, but no sufficiently robust basis for broad “anti-aging” claims. Lifestyle levers first.
LH and FSH regulate follicle and sperm maturation in women and men, but much of the “optimization” is not directly supported by RCTs of LH/FSH themselves. The strongest evidence concerns downstream hormonal findings under interventions (e.g., Metformin, acupuncture, contraceptive methods). The evidence strength varies by question.
Interactions aren’t “felt”: the strongest evidence comes from meta-analyses of RCTs or large RCT evaluations. For Fruit-Juice interactions with antihypertensives, there is a systematic meta-analysis; for GLP-1 agonists and gallbladder disease, a JAMA meta-analysis. For many supplements, however, the data is currently thin.
Chronotype (morning vs. evening type) is associated in several meta-analyses with risk for diabetes, cancer, and poorer mental health among shift workers. For depression and pain, there is also systematic evidence. For direct “performance” or therapeutic effects, the evidence base is overall more limited and often indirect.
For endurance, training and intensity management are best supported by systematic reviews (e.g., distribution of training intensities in middle- and long-distance). Supplements usually show only specific, context-dependent effects, and the overall evidence is heterogeneous. The data is sometimes strong (reviews), sometimes limited (smaller RCTs).
Observational studies can reveal associations, but they rarely prove cause-and-effect. Using five systematic reviews/meta-analyses, we clarify where results appear robust and where confounding may skew interpretation. We also classify the evidence hierarchy and derive concrete, everyday decisions—without supplement hype.
Meal timing can have measurable effects depending on your goal (glucose, appetite, metabolic circadian alignment), especially in controlled intervention trials. For cancer- and microbiome-mechanisms, the evidence is still heterogeneous and sometimes only indirect. Prioritize lifestyle levers like sleep, light, and making your eating window realistic before supplements.
Caffeine can increase alertness in some people, while sleep and recovery may suffer—potentially amplifying anxiety indirectly. However, the evidence is not consistent, and robust anxiety outcome data are limited. Prioritize sleep, timing, and dose; supplements do not replace these foundations.
Vagus-nerve interventions are most often studied using taVNS (transcutaneous auricular vagus nerve stimulation). In available studies, effects appear for specific goals such as Parkinson gait, atrial fibrillation, and certain pain or sleep indications. Evidence quality varies by indication; many questions (mechanisms, long-term effects) remain open.
Deload (a training week with reduced volume) is plausible, but direct evidence for the “best” deload form is limited. The strongest evidence from meta-analyses supports principles like training volume and frequency for muscle gain. Practically, lifestyle levers (sleep, stress, performance signals) should be prioritized over blanket percentage rules.
Red-light therapy shows benefits in several studies, mainly for vision-related issues: For childhood myopia, meta-analyses/reviews exist on repeated low-level red-light intervention, and for presbyopia there is an RCT on asthenopic complaints. For skin safety, there are RCTs with LED red-light data. For other claims, the evidence is often limited.
Grip strength is a measurable performance and health marker. For supplements, the overall evidence base for effect strength on pure grip strength is currently thin; for creatine there are RCTs for strength/training effects, but grip-strength-specific conclusions remain limited. The decisive levers are training, technique, muscle mass, sleep, and addressing causes such as inflammation.
RCTs deliver the strongest evidence, but they aren’t available for every question. Using 7 high-quality studies, we show how well effects are supported: from nutrition and weight management to supplements and medical strategies. You’ll learn which claims are robust and which are currently limited.
Geroscience biomarkers are intended to make biological aging processes measurable, but they are supported to very different degrees. The strongest evidence comes from meta-analyses and systematic reviews on epigenetic aging and inflammation/multi-disease markers. For specific intervention effects (e.g., ketone esters, calorie restriction), individual RCTs and early studies exist; however, generalizability remains limited.
Glycine is biologically plausible as a “conditionally essential” amino acid, but the clinical evidence is mixed. One meta-analysis evaluates causality with cardio-metabolic risk, while RCTs and clinical studies investigate outcomes such as plasma glycine and muscle structure (critically ill, severe obesity). We classify what the evidence does and doesn’t support: what applies, and what is still unclear.
Neurofeedback has shown measurable effects for some indications, often in RCTs or in meta-analyses focused on specific paradigms (e.g., EEG- or MVPA-based). However, the evidence is heterogeneous: goals, outcome measures, and protocols differ substantially, and not every indication is supported equally well.
Light therapy is best supported for sleep problems (meta-analysis), depressive symptoms (including perinatal depression, and in young people), and in some cases for myopia in childhood via systematic reviews. For other indications, findings are heterogeneous. Lifestyle levers such as sleep timing and daylight exposure are the foundation before using devices.
Polyphenols (especially from green tea/tea herbs) are associated in multiple meta-analyses with effects on metabolic markers, body fat, oxidative stress, and in some cases cancer prevention. However, for specific polyphenol doses and clinically “hard” endpoints, the data are currently limited. The safety profile of green tea extracts for adults is generally considered acceptable, but it does not apply equally to every situation.
Liraglutide (a GLP‑1 receptor agonist) shows, in meta-analyses of randomized studies, mainly effects on weight and metabolic outcomes in appropriate patient groups. For details on safety, body composition, and specific indications (e.g., pregnancy/PCOS), the strength of conclusions depends on the available study evidence.
Curcumin shows effects across several disease areas in current systematic reviews and meta-analyses (e.g., diabetes/prediabetes, lipid measures, kidney function, and in some cases mucosal inflammation). However, for many mechanisms, the evidence is only indirect. Data quality varies by outcome and often doesn’t reach the level of clear clinical efficacy.
For obstructive sleep apnea, CPAP demonstrably improves certain measured outcomes such as blood pressure in meta-analyses. For additional outcomes (e.g., cancer risk), the data are limited to a small number of RCTs and are not clear. Lifestyle levers like sleep, weight management, and treating triggers remain the foundation.
Sleep pressure rises with time awake and affects cognition, perception, and neuronal excitability. In meta-analyses, sleep-deprivation scenarios consistently show measurable functional losses. For inflammation, the microbiome, and mood, review papers also provide signals, but effects vary by setting. Lifestyle levers—sleep duration, sleep timing, and recovery—should take priority over supplements.
Restless Legs (RLS) is common, but the evidence varies widely by treatment. Meta-analyses of tonic motor activation and AASM guidelines assess effectiveness and safety, usually with measurable effects on RLS severity and sleep. For some non-drug approaches, evidence is limited—e.g., in patients undergoing hemodialysis.
Berberine has been investigated in several current meta-analyses with improvements in individual metabolic parameters (e.g., obesity indices, lipids) and in sub-areas such as non-alcoholic fatty liver and PCOS/infertility. However, the strength of the data differs by indication; study quality and design are decisive for any concrete dose/safety takeaways.
CBT-I is the most studied non-drug treatment for insomnia. Meta-analyses (including 2024, 2022, and 2015–2016) support improvements in sleep quality and often also associated symptoms like anxiety/depression. For special groups and mobile/internet formats, there are separate findings, sometimes mixed and heterogeneous.
Peptide Therapy is an umbrella term for very different compounds and applications. In the available studies, evidence is mostly supported by individual, indication-specific effects—often from systematic reviews and selected RCTs (e.g., heart failure, celiac disease). Many other claims are currently limited or constrained by study design and overall study quality.
Creatine is considered by many to be a well-working supplement for strength and muscle building, supported by meta-analyses among other sources. For kidney safety, cognition, and several performance aspects, there are also reviews — but not every use-case has equally strong data. Lifestyle levers like training, nutrition, and sleep remain the foundation.
Deep sleep (Slow-Wave/N3) is quantified via sleep measurements, yet many claims about “effects” come from indirect biomarkers or from clinical groups. The available meta-analyses mainly support associations (e.g., alcohol/sleep, Slow-Wave activity in depression, spindles in sleep apnea). Lifestyle levers typically come before supplements.
Time-Restricted Eating (time-limited eating) is associated in meta-analyses with moderate weight loss and improvements in metabolic risk factors, and in some cases with diabetes. Effects on sleep appear small to mixed. Data on hunger and practicality are consistent: hunger can increase. Dosage and long-term safety vary across studies; overall, the evidence is predominantly based on randomized short- to medium-term trials.
Carbohydrate periodization can influence substrate use, glucose and lipid responses, and training adaptations depending on the setting. Meta-analyses support effects for acute and context questions (e.g., fasted vs. fed), but a clear “always better” periodization for everyone is not established. Lifestyle levers like sleep, training timing, and total energy intake remain the foundation.
Vagus nerve stimulation (VNS) is mainly established for therapy-resistant epilepsy, supported by systematic reviews. For stroke, spinal cord injury/quadriplegia, and rehabilitation, there are promising RCT and practical application data. Lifestyle levers like sleep and load management remain a key foundation.
Mitochondrial Health is usually assessed in studies using markers such as muscle adaptation, training-related effects, and certain biomarkers. For movement interventions, evidence from randomized studies and meta-analyses is strongest. For supplements, the evidence base is often animal-based or indirect. This article categorizes findings by study quality.
Apigenin has been investigated in several meta-analyses on inflammation, oxidative stress, cancer signaling pathways, and possible neuroinflammatory aspects—primarily in preclinical models. For safe, effective dosing in humans, there are currently no robust RCT data. Prioritize sleep, movement, and nutrition; apigenin is best viewed today as a research rather than a therapy component.
In meta-analyses, Beta-Alanine shows the clearest performance gains mainly in intensity-near, short- to moderate-duration efforts, explained by increased muscle carnosine buffering. For “responsiveness” between individuals, a large IPD analysis finds little clear evidence. Data on body composition and metabolism are mixed; safety at typical study doses has generally been reasonably well investigated.
Caloric Restriction (calorie reduction) lowers body weight in many RCTs and can improve some cardiovascular risk factors. Meta-analyses also suggest differences between dietary patterns (e.g., intermittent vs. continuous approaches). For inflammation and muscle mass, effects are plausible but not consistently observed across all outcomes. Specific effects depend on the population and study methods.
The circadian rhythm influences sleep, mood, cardiovascular parameters, and metabolism-related associations. In multiple meta-analyses, the relationship to intervention approaches such as exercise and light is well studied—while details about causal mechanisms, optimal doses, and long-term safety are often limited or only supported indirectly.
Citrulline Malate has been studied most for performance and workload parameters in resistance and interval training. Meta-analyses suggest effects mainly on training repetitions and some fatigue/load-related measures, while individual RCTs (e.g., German-Volume-Training) find no benefit. Lifestyle levers such as sleep, training technique, and workload management should be prioritized over supplements.
Coenzyme Q10 (CoQ10/Ubiquinol) has been studied in multiple meta-analyses for depression/fatigue, blood sugar, metabolic markers, adjunct periodontal therapies, and training-related effects. The evidence level differs by target area: sometimes statistical improvements in biomarkers or symptoms, sometimes inconsistent effects and limited generalizability. Lifestyle levers such as sleep, movement, and diet remain the foundation.
DHEA can change, among other markers, testosterone and IGF-1 values in several meta-analyses, while effects on metabolism, fat mass, blood pressure, lipids, bone, and depression appear to vary depending on baseline status. Evidence is heterogeneous for many endpoints; lifestyle levers should be prioritized over supplements.
“Estrogen Balance” is not a clearly defined biomarker, but a concept spanning hormone status, metabolism, and tissue outcomes. Strong evidence exists for certain estrogen-related therapy decisions in the breast cancer context (including systematic reviews). For general lifestyle- or supplement-related effects, the data are often indirect or limited.
HMB (β‑Hydroxy‑β‑Methylbutyrate) shows in several meta-analyses mainly moderate effects on muscle quality, body composition, and functional parameters—especially in older people—while results in younger people are often less consistent. For endurance and general training goals, findings are heterogeneous. The evidence for safety is overall limited and is often better when HMB is used alongside movement rather than without.
Caffeine reliably increases alertness and can improve performance in the short term; how strong the effect is depends on factors like habitual intake and genetics. For sleep/EEG and migraine, the evidence is more nuanced. Many effects are dose-dependent, but not everything is well supported—part of the data is currently limited.
Micronutrients help most reliably when a deficiency is likely or when targeted supplementation/fortification has been tested. The strongest evidence often comes from systematic reviews and meta-analyses of RCTs—for example, in pregnancy and children in countries with supply gaps. Many effects are context-dependent: population, baseline status, dose, and duration determine outcomes.
Nutrigenomics aims to tailor nutrition to genetic risk. In the study landscape, personalized nutrition approaches are more often tested via RCTs and meta-analyses for behavior and risk indicators, while truly direct gene-based mechanisms often remain indirect. For many claims, the data are heterogeneous and limited depending on the endpoint.
Sprint training can improve fitness, explosive power, and performance-relevant markers, but the strength of effects depends on the interval type, total volume, and the target group. The evidence base usually comes from controlled training comparisons and systematic reviews; broad claims like “sprints are always best” are too short-sighted.
Thymosin Alpha-1 is studied as an immunomodulator across several disease areas. For chronic hepatitis B, meta-analyses assess it in combination with interferon or with antiviral baseline therapy; for COVID-19, sepsis, and in parts of cancer, systematic reviews/meta-analyses also exist. Evidence on dose and safety is mainly summarized from clinical studies, but it is not equally robust for every intended use case.
Thyroid Function influences health across multiple domains, but the strength of evidence varies: there are meta-analyses for exposures (e.g., sodium/iodide-transporter inhibitors, fine particulate matter) and for interventions such as exercise in hypothyroidism. For many everyday questions, however, direct RCTs are missing; observed associations are not automatically causal.
Vitamin B12 is clinically relevant mainly when a deficiency is present or when risk groups are affected. In vegan/vegetarian overviews, systematic reviews show measurable differences in status. For specific conditions, much of the data is observational; few effect-testing studies exist. Lifestyle levers like diet, sleep, and medical diagnostics should come first.
Vitamin D matters most in deficiency states: for knee osteoarthritis, pregnancy, preterm infants, and rickets, current meta-analyses show either clear effects or supply-related problems in parts of the evidence. For many “other” outcomes (e.g., biological aging), evidence is more indirect or consistently inconclusive rather than definitive. Lifestyle (sunlight, activity, diet) remains the foundation.
For L-Tyrosine, there is unfortunately no robust, supplement-specific evidence in the provided sources. The referenced meta-analyses mostly address tyrosine-related drug or therapy classes in oncology/immunology and do not evaluate L-Tyrosine as a dietary supplement. Prioritize sleep, light, movement, and nutrition first; in this source set, supplement effects are not adequately supported.
Testosterone is investigated very differently depending on your starting point and goal. For clinical questions, studies often use meta-analyses of RCTs or systematic reviews—for example on the cardiovascular safety of testosterone replacement and on postoperative outcomes. Where results are indirect or animal-based, the data are limited.
Progesterone has been studied most thoroughly in reproductive medicine. In meta-analyses, it shows benefits—e.g., within standard HRT-FET regimens—and there are indications regarding risks related to preterm birth and certain pregnancy complications. Outside clear indications, the data are often limited. Lifestyle levers such as sleep, body weight, and stress planning should be prioritized before considering supplements.
Meta-analyses summarize many studies and often provide the best overall assessment—however, their conclusions depend on study design, heterogeneity, and risk of bias. This overview uses the 12 works mentioned, ranks evidence by strength, and highlights typical gaps: correlation instead of causation, uncertain effect sizes, and areas where data are thin.
The Mediterranean diet is associated in multiple meta-analyses with reduced risks and improvements across cardiovascular, metabolic, and other endpoints. The available overview papers (including meta-analyses from 2026) are especially strong for prevention. For specific dose-/timing effects, the data are usually limited.
St. John’s Wort has been studied most for depressive symptoms. In several meta-analyses of randomized studies, it shows effectiveness comparable to certain antidepressants, but data quality and effect sizes vary. Key point: the risk of interactions is high, so medical input is essential before taking it—especially if you use medications.
Methylene Blue has been studied in multiple meta-analyses, mainly in critical illness (distributive shock, septic shock), perioperative settings, and certain inflammations in the mouth and throat. The evidence quality varies by indication: for some endpoints, meta-analyses suggest benefit; other outcomes remain unclear or are only indirectly supported. Lifestyle levers should be prioritized over supplements.
Metformin is best studied for type 2 diabetes; many added benefits (e.g., osteoarthritis, tumor survival) have meta-analyses, but effect strength varies. For pregnancy and chronic kidney disease, there are systematic reviews on safety. Not everything is based on RCTs—so the evidence must be evaluated separately.
Contrast therapy (alternating warm/cold) shows moderate benefits in multiple meta-analyses for recovery after exertion and sometimes pain reduction for muscle soreness. Clear superiority over other approaches is not consistent; results depend on the endpoint. Safety data and guidance on dose/timing are limited, so use it cautiously and individually.
L-tryptophan is linked to the kynurenine/indole metabolic pathway. From the available meta-analyses, you mostly get inferences/signal pathways, while direct clinical effects on sleep or mood in this set cannot be clearly quantified. Lifestyle levers like sleep, movement, and stress management should remain the priority before supplements.
Glycine is often suspected to promote sleep, but the robust clinical evidence for specific sleep parameters is not as strong as for established sleep interventions. At present, there are not yet clear, consistent RCT data supporting the desired effect. Prioritize sleep hygiene, light control, and behavioral therapy; only then consider supplements.
“Floating” is studied differently depending on the context (e.g., “floating needles” in medicine or “floating” in environmental datasets). For intended “floating tank / flotation room” floating, the 28 studies listed here are not a direct evidentiary basis. The meta-analyses mainly show benefits in specific medical indications—not a general “floating” effect.
CRP is an inflammatory marker, and changes can be measurable depending on context (infection, surgery, sleep deprivation) across many studies. By contrast, a “CRP effect” is usually not directly testable, because CRP is primarily a diagnostic signal. What matters is evidence quality, the target population, and study design.
CJC-1295 is a long-acting analogue of growth-hormone–releasing hormones that, in one RCT, can stimulate GH and IGF‑1 secretion over a longer period. However, for broad use in humans, the existing studies are limited and often indirect. For effectiveness, dosing, and safety outside clearly defined indications, the evidence is currently insufficient.
Sleep architecture describes the structure and distribution of sleep stages. In certain conditions (e.g., sleep apnea), multiple meta-analyses show measurable changes under interventions such as exercise, PAP therapies, and weight loss. For many “biohacks,” however, high-quality RCT data are missing; the evidence is often condition-specific.
PT-141 (Bremelanotide) has been investigated for a specific form of sexual dysfunction and evaluated in multiple RCTs; meta-analyses and systematic reviews support efficacy on relevant endpoints, but effect sizes and individual subgroups vary. Evidence on long-term safety and across all potential target populations is limited.
The Omega-3 Index (EPA+DHA in erythrocytes) is linked in large studies to disease risks and tested in meta-analyses as a driver of multiple endpoints. For heart mortality and diabetes, there is solid evidence from meta-analyses. For cognition, effects depend on baseline values. For prostate cancer and other topics, the evidence is heterogeneous.
Power naps may support memory consolidation, sport-related performance, and subjective recovery depending on the context. However, the study base is heterogeneous: meta-analyses show effects in early childhood, in specific performance domains, and in observational relationships, while health risks are not causally clear. Timing and night-sleep quality are decisive.
In research, sauna and other heat therapies are most often studied indirectly—through temperature management, hyperthermia in oncology, and pain/wound healing. As a result, the evidence base for “classic” sauna effects is often limited. Meta-analyses on hyperthermia suggest benefits in some contexts, but not for every goal and not without specific conditions.
Photobiomodulation can show measurable effects depending on the indication (e.g., pain/function in TMJ, wound healing in venous ulcers, support for dental/oral problems, and depressive symptoms). The strength of the evidence varies and depends strongly on the target population and study design.
Modafinil is best supported for disease-related daytime sleepiness and certain psychiatric indications, with less consistent evidence for general “performance enhancement.” Several meta-analyses report effects, but benefit size and side-effect profiles depend on the indication. Lifestyle levers like sleep quality should come first because they often provide larger benefits with a better safety profile.
In several meta-analyses, RCT data for ginger is strongest for chemotherapy-associated nausea/vomiting, certain weight and fat-related parameters, and glycemic effects in type 2 diabetes. Evidence is often insufficient for broad claims like “anti-inflammatory” or strong all-round effects beyond explaining heterogeneity. Dose and extract form vary substantially across studies.
The glymphatic system is often linked to “waste removal” in the brain and better overnight “detox.” However, the human evidence for true effectiveness is heterogeneous, highly method-dependent, and often indirect. Sleep, movement, and light regulation are plausible lifestyle levers, but hard endpoints are still limited.
A VO2max test is primarily a measurement task (performance capacity or aerobic capacity), not a “miracle tool.” The available evidence mainly supports training and training-context effects on aerobic fitness, but not always the superiority of individual test protocols. Lifestyle levers—training and load management—remain central.
In several meta-analyses, CGM lowers—sometimes measurably—relevant glucose metrics in people with diabetes, and it may improve perinatal endpoints in pregnancy. For general “wellness” effects, the data is often limited. The evidence is strongest where RCTs exist.
Progressive muscle relaxation (PMR) may improve sleep quality and mental complaints. The strongest overall claim comes from systematic reviews and meta-analyses of randomized trials. For precise dose–response relationships, the data are often limited. Use PMR as a short-term relaxation strategy and prioritize sleep, movement, and light.
In practice, ligaments and joints are influenced mainly through surgical strategies and rehabilitation design. For ACL and MPFL injuries, meta-analyses exist for outcomes such as stability and function, as well as for comparisons of different treatment approaches. But for broad “strengthen ligaments” promises, the evidence is often thin—so lifestyle levers remain the standard.
ZMA (zinc, magnesium, often additionally vitamin B6) is popular for sleep and recovery, but the specific evidence from the provided sources is not unambiguous. Most of the cited reviews address B-vitamins in other contexts. Therefore: optimize sleep, nutrition, and a possible deficiency check first, and only consider supplementation in plausible deficiency/special situations.
What helps with anxiety depends on the cause, and the evidence varies. Meta-analyses particularly support non-drug approaches—especially movement/training and specific therapies—while medication data are context-dependent. For ketogenic diets, GLP-1 receptor agonists, and animal studies, the data is limited. This post organizes evidence, benefits, limitations, and risks.
ALCAR is best supported for specific indications: for diabetic peripheral neuropathy, there is Cochrane-backed evidence; for male infertility, multiple meta-analyses show average improvements in semen parameters, though not necessarily pregnancy rates. For other goals (e.g., cognition or general “energy”), the data are inconsistent or limited.
Foam Rolling in studies often shows short-term effects, such as pain perception or tissue stiffness, but less consistently improves performance or long-lasting range of motion. In meta-analyses, Foam Rolling/Stretching sometimes does not outperform other warm-up methods. Training and recovery effects appear limited and vary.
Vitamin C for “recovery” after exertion appears inconsistent: a current meta-analysis on post-exercise recovery finds no consistently clear superiority over placebo overall. For other disease contexts, there is targeted evidence in places, but that does not automatically translate to sports “recovery.” Lifestyle levers like sleep, nutrition, and training load management are usually stronger.
Alpha-GPC provides choline, but the specific evidence base for “Alpha-GPC” as a substance is currently thinner than the broader choline literature. The available meta-analyses usually focus on choline/betaine in populations (e.g., pregnancy, diabetes risk) or related questions. For specific effect claims, you need RCT data; the current dataset is limited.
Beetroot (sodium nitrate/nitrate from beetroot) improves measurable vascular and blood pressure markers in many RCTs and may support endurance performance depending on the setting. Evidence is heterogeneous (dose, duration, baseline diet, participants). For effects on performance/“ergogenicity,” there are meta-analyses, but results are not consistently positive across all outcomes.
Glucosamine has been studied most for joint problems: meta-analyses assess effectiveness in knee osteoarthritis and temporomandibular joint complaints, including safety data. Outside joints (e.g., diabetes and cancer prevention), findings sometimes rely on MR analyses or other lower-grade evidence. Dose and long-term safety remain limited within each indication.
Ginkgo biloba (e.g., EGb 761) shows effects for specific indications in several meta-analyses—such as mild dementia, sudden hearing loss (as an add-on), or unstable angina pectoris. For other goals, such as Alzheimer’s, the data are mostly heterogeneous and sometimes rely more on preliminary or mechanistic work. Overall: benefits are indication-dependent; the strength of evidence varies.
Brain fog is a symptom cluster that varies in strength depending on the cause (e.g., long Covid, chemotherapy, multiple sclerosis, migraine, or trauma-related outcomes). For specific interventions, there are meta-analyses (e.g., TES in MS, cognitive/social training approaches), but many causes have only indirect data. Priority: sleep, movement, light, and inflammation/stress management before supplements.
Saffron and Crocin show clinical hints across multiple meta-analyses, especially for depressive symptoms and for markers of inflammation and oxidative stress. For diabetes, prediabetes, and metabolic disturbances, there are positive but heterogeneous effects. For dosing, long-term safety, and clearly defined mechanisms, the data are still not consistently strong enough.
Stress resilience is partly measurably improved, especially through non-medication interventions such as mindfulness and structured programs for psychological relief. For “biological aging,” an association with lifetime stress is supported in observational studies, but causality is less certain. Lifestyle levers (sleep, light, movement, stress management) remain the foundation; supplement evidence is not the primary support here.
Growth hormone and IGF‑1 are biologically plausible through growth, tissue remodeling, and metabolism—yet clinical efficacy varies by indication. The available evidence mainly comes from systematic reviews and meta-analyses of hormone therapy for growth hormone deficiency and related questions. Lifestyle levers (sleep, training, energy availability) should come first.
Taurine has been examined in several meta-analyses, showing improvements in metabolic markers, cardiovascular endpoints, and sometimes cognitive or performance-related outcomes. However, for specific real-world daily dosing, the evidence is heterogeneous, and many effects are not clearly consistent. This article separates what is supported by RCTs from what remains open.
Immune modulation is not a “one-size-fits-all.” In several meta-analyses, effects depend on the condition (e.g., skin, gut, severe illness, cancer response). For general health claims, the evidence is often limited. Lifestyle levers such as sleep, nutrition, and reducing inflammation should be prioritized first.
Clinically, insulin resistance can be assessed with multiple indices—not only by a single “insulin value.” For improvements, there is solid evidence for lifestyle interventions (especially exercise) and for some complementary approaches; however, much of the evidence outside randomized designs remains unclear. Studies should be evaluated separately by evidence strength.
5-HTP has been evaluated for depression in several meta-analyses and Cochrane-style reviews; the data are not uniform, but there are indications of an antidepressant effect. For panic, smaller RCT data suggest neuroendocrine/biochemical effects. Safety risks such as serotonin syndrome are mainly discussed in preclinical review papers. Evidence for body composition is currently limited.
Phosphatidylserine (often as a soy-lecithin or PAS complex) has been studied in individual RCTs for specific targets—for example, cognition in mild cognitive impairment and stress-reactivity under chronic stress. The evidence is topic-specific: not everything is supported equally well. For safety, there are limited but relevant RCT signals, depending on the studied population.
The blog clarifies which factors can most reliably be measured as influences on the autonomic nervous system (e.g., heart rate variability), and where the data is uncertain. Meta-analyses support robust effects from mobilization/training, while also showing limits related to measurement and analysis questions. Lifestyle comes before supplements.
REM sleep has mainly been studied through the diagnosis of REM sleep behavior disorder (RBD), associations with neurological conditions, and the effects of REM deprivation. The evidence is strong for some outcomes (e.g., RBD quantification), but limited for others (causal claims about training/supplements are mostly missing). Sleep and lifestyle levers should come first.
Rhodiola rosea shows potential benefits in several systematic reviews for stress/performance and in cardiovascular indications, sometimes based on RCTs. However, for many psychological or cognitive effects, the data are heterogeneous or largely preclinical. A clear standard dose is often missing; product quality and safety can vary by use-case.
Magnesium shows indications of better “recovery” parameters in some situations, most often as intravenous magnesium sulfate in operating-room/anesthesia contexts. For general muscle recovery or “recovery” in everyday life, the data must be broader checked and is often indirect. The available evidence is heterogeneous; lifestyle levers like sleep and movement remain the primary focus.
Massage Therapy has varying strengths of evidence depending on the indication: for some complaints there are meta-analyses, for others the data are sparse or the endpoints are too nonspecific. For many issues, the biggest lever is often outside manual therapy—movement, sleep, pain management, and targeted physiotherapy. Supplements are rarely necessary.
Mindfulness shows in high-quality studies mainly small to moderately positive effects on stress, anxiety, and depressive symptoms—often time-dependent and influenced by program quality. Evidence for sleep, cognition, and performance is mixed. Lifestyle levers such as sleep, movement, and light exposure remain the priority.
Hyperbaric oxygen (hyperbaric oxygen, HBO) plausibly works via increased oxygen density, but the evidence varies strongly by indication. In several areas (e.g., certain wound and emergency settings), there is relatively solid evidence, while effects for sport, anti-aging, or cognitive goals are often limited. Data quality varies widely.
NSDR (Non-Sleep Deep Rest) is a hypofunctional recovery modality with a growing research base. Some studies suggest improvements in stress, recovery, and subjective wellbeing, but the strength of evidence varies by outcome. Lifestyle levers like sleep, movement, and light remain the first priority.
Sleep hygiene improves sleep for many people, but not every single recommendation is supported equally well. In meta-analyses, behavior-based interventions (including stimulus control, restrictive time in bed, sleep pressure) often show the strongest effects. Some “tips” like avoiding screens are more mixed. Key point: tackle sleep problems in a structured way—lifestyle levers first, supplements second.
Tesamorelin (GHRH analogue) is best supported for reducing visceral fat in HIV-associated lipodystrophy. For other goals like muscle building, performance, or general “longevity,” the data are sometimes limited. Safety has been studied fairly well, but it still requires caution in specific risk groups.
Strength training improves strength, muscle mass, metabolic markers, and often also function and quality of life. The evidence base is strong in many areas (RCTs, sometimes meta-analyses), but it varies depending on your goal (e.g., cognition or “longevity”). The deciding factors are progressive overload, training frequency, and sufficient total weekly dose.
Glutathione as a dietary supplement is plausible, but the human evidence varies by target area. How strong the effect is depends heavily on study design, dose, and bioavailability. Prioritize sleep, movement, nutrition, and avoiding smoking over supplements. The best evidence differs: sometimes it focuses on metabolic and antioxidant markers, not consistently on clinical outcomes.
Retatrutide is a novel compound investigated in multiple randomized studies, mainly for overweight and obesity clinical endpoints. The data come primarily from Phase 2/3 studies; long-term safety and true long-run effects are not yet conclusively established. We hierarchically classify the evidence here.
In RCTs, meditation and mindfulness usually show moderate effects on stress and depressive symptoms, and sometimes on anxiety and sleep. For cognition and long-term health, the data are heterogeneous. Method and study duration largely determine outcomes; many endpoints are still insufficiently replicated.
Active Recovery (light training after a workout) can improve muscle soreness, pain perception, and perceived recovery for many people, but effects are not always consistent. The evidence base is mostly RCT-based, with heterogeneous protocols. Lifestyle levers such as sleep, training load management, and nutrition remain the most important levers.
Cold Exposure can affect mood, stress responses, or affective state in the short term for some people, but the evidence strength varies across target populations. There are meta-analyses and RCTs for psychological endpoints; however, protocols are often heterogeneous, follow-up is frequently short, and measurement outcomes are not uniform.
GABA supplements show limited, not consistently reproducible evidence across randomized trials, depending on the target domain. For sleep, stress, or cognition, benefits appear in some studies but not clearly in others. Sleep, exercise, light exposure, and stress-management strategies remain central. Overall, the data on dosing and safety are limited.
Training intensity measurably affects performance capacity, fat mass, and cardiovascular health—especially when higher intensities are combined with sufficient volume. Evidence is strong for endurance and mixed for strength/muscle retention. Results generally reflect group averages; individual responses vary. There is no universal “best” intensity.
For depression, robust evidence exists mainly for psychotherapy, antidepressants (depending on diagnosis/severity), and lifestyle interventions such as exercise, sleep, and light. Effect sizes vary from study to study. Add-ons are usually only limitedly supported. The evidence base ranges from meta-analyses to animal studies—the differences matter.
Maximal strength is trained primarily through progressive resistance exercise; in RCTs and meta-analyses, the outcome measures and effects are generally quantifiable. For add-on methods (e.g., supplements, recovery aids), the evidence is often weaker or depends strongly on context and study conditions. Here, we separate evidence from speculation—briefly and grounded in studies.
EAAs (complete essential amino acids) and BCAAs (leucine, isoleucine, valine) can support muscle protein synthesis and recovery—especially when dietary protein intake is insufficient. For sports performance, effects are variable and highly context-dependent. The evidence base is heterogeneous; safety is usually unremarkable at typical amounts, but data on long-term outcomes are limited.
Pneumatic Recovery (NormaTec) can improve some people’s perceived recovery after exertion. The evidence base mainly includes RCTs on athletic performance and recovery, but device protocols vary substantially. Clear statements about long-term effects and safety are often limited by inconsistent study design and insufficiently robust effect sizes.
EMDR/trauma therapy can be effective for many groups; the strongest data come from randomized controlled trials and meta-analyses. Still, effect sizes vary depending on the trauma type, the comparison group, and the measurement tool. This post breaks down what is robustly supported, where the evidence fluctuates, and how to judge study quality.
Zinc can help when a deficiency is documented and in specific situations (e.g., the duration of a cold). For many “longevity” claims, the evidence is weak or inconsistent. What matters is the evidence level (meta-analysis/RCT), baseline context: diet/sleep/infection risk, and dosing including upper limits and interactions with iron/Cu.
Based on the current state of research, whey and casein mainly support muscle gain or maintenance by providing essential amino acids—especially **leucine**. The RCT evidence for measurable effects alongside resistance training is strongest. By contrast, many conclusions about “longevity” and “fat loss” are limited in scope.
SAMe is most often studied for depression and, to some extent, for osteoarthritis. Systematic reviews and meta-analyses generally report favorable effects, but the overall data quality varies. For other “CNS/health” claims, evidence is thinner. Safety: possible side effects; relevant caution with depression and medication interactions; prioritize lifestyle levers first.
The evidence base on alcohol is clear: for treating alcohol use disorders, multiple meta-analyses exist for medications such as naltrexone, acamprosate, nalmefene, baclofen, and topiramate. For health effects of alcohol outside addiction treatment, the evidence is heterogeneous. Lifestyle levers (sleep, movement, stress management, substitution/structure) are often the first step before supplements.
HbA1c reflects average blood glucose over the past weeks and is central for diagnosing and monitoring diabetes. For clinical decisions, HbA1c is established in guidelines; links to complications (e.g., retinopathy, kidney disease) are plausible based on meta-analyses. Data on HbA1c variability are also growing, but not consistently strong across outcomes.
Sauna can affect blood pressure and circulation markers in the short term, and for people with cardiovascular disease it may be safer than uncontrolled heat exposure, but the data is strongest for specific endpoints. For “recovery” in the sense of sports performance/fitness improvement, effects are sometimes indirect and the methods across studies vary.
Semaglutide is well supported for weight loss in people with obesity/overweight, with multiple meta-analyses and systematic reviews. For safety, current pooled analyses exist, but side effects depend on both dose and the individual patient. Meta-data from RCTs also covers cardiovascular effects, though the details vary by population and endpoint.
Magnesium may improve sleep quality in some people, but the evidence is not consistent and depends strongly on baseline factors (e.g., deficiency). Meta-analyses support some effects, but not all outcomes. For better results, prioritize sleep, light, movement, and nutrition; magnesium remains a supplemental lever.
In studies, yoga shows benefits mainly for stress and stress-related markers, as well as certain pain and osteoarthritis outcomes. For sleep and cardiovascular parameters, the evidence is promising but sometimes based on small or narrowly designed studies. Methodologically, the data are heterogeneous: study formats, duration, and primary endpoints differ substantially.
Tirzepatide has shown effectiveness in multiple randomized trials (RCTs) for the treatment of type 2 diabetes and for weight reduction; effects are dose-dependent and comparatively well quantified. However, data on long-term outcomes outside clearly defined indications are limited, and safety considerations require careful risk–benefit assessment with medical supervision.
Selenium may show targeted effects on specific metabolic and immune markers depending on your starting status (low selenium vs. adequate intake). However, for many claimed “longevity” or performance benefits, the data is inconsistent or limited. Supplementation is dose-dependent: taking too much can be harmful.
Vitamin B-complex is mainly useful when there is a deficiency or when specific risk groups are affected (e.g., elevated homocysteine levels). Many effects outside deficiency states are inconsistent or only weakly supported in RCTs. Key takeaway: lifestyle (diet, sleep, alcohol) before supplements.
For the post-workout window, the best-supported levers are nutrition (protein amount; carbohydrates if needed), sufficient total daily protein, and sleep. Many “hacks” have limited data. We rank 11 high-quality studies by strength of evidence, name measurable effects, and clarify where research is missing or results are inconsistent.
Recovery Nutrition likely helps mainly through timing and appropriate macronutrients after exercise (e.g., protein for muscle protein synthesis, carbohydrates for glycogen replenishment), while many “extra” claims are only weakly supported. The strongest evidence comes from RCTs and meta-analyses on protein and carbohydrates—especially when combined with adequate overall energy balance and sleep.
Nootropic Stacks are often blends without robust validation data. For individual ingredients, there may be RCTs depending on the substance, but high-quality studies for the “stack” combinations are usually missing. Prioritize sleep, movement, light, and nutrition; supplements can complement, but only when the target effect is supported and safety information is clear.
Blue light demonstrably influences wakefulness via the light input to the visual system and can worsen sleep when used at the wrong time. Evidence for broad health outcomes is inconsistent depending on the endpoint. We classify RCTs, meta-analyses, and observational studies—plus practical, supplement-free steps—into what is more or less solid.
Sleep tracking can help you understand sleep patterns, but accuracy for individual parameters on consumer devices is limited. Systematic reviews show valid results mainly in group comparisons versus polysomnography, with measurement scatter. For better sleep quality, lifestyle changes—and for insomnia, behavior therapy—remain central.
Increasing telomere lengths is only plausibly achievable with a few approaches that have reasonably good evidence. Meta-analyses suggest measurable effects mainly for movement/exercise, lifestyle interventions, and—sometimes—social support, but these effects are usually small. For “ALT/other” telomere mechanisms there are signals, but they are primarily relevant in tumor contexts.
Tendon health improves more reliably when you optimize load, movement, body weight, sleep, and recovery first. The strongest evidence level comes from training and rehabilitation approaches; much of the supplement evidence is limited. What matters most is which tendon problem you have and whether the data come from RCTs, observational studies, or animal research.
“Sleep as Recovery” is plausible as a concept, but the evidence differs: for specific interventions there are meta-analyses (e.g., sleep restriction, melatonin, movement formats, and sometimes hypnotics). However, the data are often for single endpoints such as sleep quality rather than direct “recovery” of other systems. Lifestyle levers have priority over substances.
Sulforaphane are often marketed for health effects, but the evidence quality varies strongly by endpoint. For robust claims, you need large, well-designed RCTs or meta-analyses; for many statements, the data is limited. Lifestyle levers like activity, sleep, and diet are usually the stronger “switches” to focus on first.
Load Management means steering training/treatment burden so symptoms decrease without increasing risk. The studies used here are mainly meta-analyses and systematic reviews of load-adjacent therapeutic concepts (e.g., shoulder/back pain). The evidence is strongly dependent on study design and analysis choices.
HIIT improves measurable fitness and performance markers in many meta-analyses, especially cardiovascular performance (VO2max/CRF). For cognition, there are also positive effects in reviews, but findings depend more strongly on study design and population. The optimal dose and best protocol aren’t “one size fits all.” Side effects/risks depend on baseline status and how training is programmed.
Sleep onset latency is usually influenced most strongly by behavior-adjacent factors (sleep hygiene, light/timing, movement). For supplements, the evidence base varies by substance: melatonin often shows effects, while other options—including trazodone—must be judged by their specific benefit–risk profiles as evaluated in studies. Evidence for many “tricks” is limited.
Cold therapy (e.g., cryotherapy chamber or cold-water immersion) is often marketed for recovery and performance goals, but the evidence for clear, clinically meaningful effects is inconsistent. This overview categorizes evidence by study design, highlights common analysis pitfalls, and explains what is currently supported—and what remains open.
Microbiome modulation often sounds straightforward, but effects are heterogeneous: outcomes depend strongly on baseline status, the intervention, and study design. This overview organizes RCTs, observational studies, and animal data—and explains why many nutrition meta-analyses are methodologically shaky. You’ll learn how to identify robust evidence rather than plausible-sounding assumptions.
Breathwork can improve stress, mood, and physiological arousal in randomized studies and may be helpful for certain breathing- and pain-related topics. Meta-analyses support effects most consistently for stress/mental health and related indications. However, for specific breathing techniques, dose, and long-term safety, the data are sometimes still inconsistent.
Compression Recovery can partly improve DOMS and measurable recovery, but effects vary by outcome and study design. Meta-analyses repeatedly show benefits, especially for delayed-onset muscle soreness (DOMS), yet there is no universal “miracle effect.” Proprioception and performance improve only in specific situations; safety is generally well covered in the available data.
Cortisol can be influenced through lifestyle, but “lowering cortisol” is not automatically the same as “being healthier.” The evidence depends heavily on how cortisol is measured and on study design. Use an evidence hierarchy (RCTs before observational work), assess the risk of bias, and limit your conclusions when data are limited.
Sleep cycles are often marketed as an “optimization lever,” but the underlying, robust evidence depends heavily on study design. This overview ranks the evidence, explains the limits of meta-analyses (models, error sources), and clarifies what cannot be safely inferred without solid primary data.
In studies, binaural beats and sound therapy can affect cognition, stress, and sometimes tinnitus, but the strength of the evidence varies by endpoint. One meta-analysis supports benefits for cognition/anxiety/pain, while additional RCTs in tinnitus show mixed results, often with combined approaches. Safety data is limited.
Intermittent fasting is in meta-analyses usually associated with measurable improvements in weight and some metabolic markers. For type-2 diabetes, the data show short-term effects that sometimes fade after stopping. For preventing cardiovascular disease, results are more indirect, and evidence quality varies.
Bacopa monnieri is studied mainly for memory and other cognitive endpoints. In a meta-analysis of randomized studies, there are indications of cognitive effects, but the magnitude depends strongly on the study design and the endpoints used. Newer reviews also summarize safety data; however, robust dose and bioavailability guidance is limited.
A ketogenic diet can improve weight loss, blood sugar and triglyceride levels, and reduce seizure frequency in certain epilepsy forms. For many other goals, effects are smaller or the data is inconsistent. The evidence strongly depends on study design, target population, and study duration; lifestyle fundamentals are often the more decisive factor.
The best evidence for better insulin sensitivity comes from weight loss, higher fiber intake, fewer highly processed carbohydrates, and an overall lower-energy diet. Effects are usually moderate and depend heavily on starting weight, calorie balance, and adherence. For many supplements, the data are much weaker than for nutrition and lifestyle.
NAD+ precursors such as NMN and NR often raise NAD+-related markers in human studies, but clinical benefits remain inconsistent and usually small. For sleep, longevity, or clear performance gains, the current evidence is insufficient. Safety looks acceptable in studies overall, but long-term data and clear benefit signals are still lacking.
Creatine Monohydrate is one of the best-studied supplements: the evidence supports better short-term performance and more strength or lean mass, especially when combined with training. For endurance, the benefit is smaller and less consistent. Safety data are overall reassuring, but caution is needed in kidney disease.
Omega-3 fatty acids are biologically plausible and well studied, but their effects depend heavily on the goal, the dose, and the form. For cardiovascular prevention, the data are mixed; for broad “health” claims, the evidence is clearly weaker. Sleep, diet, and fish intake are more important levers than supplements.
Melatonin is not a strong sleeping pill, but in several meta-analyses it can moderately shorten sleep-onset latency, especially for jet lag, shift work, and delayed sleep phase. The best foundation remains sleep hygiene, light control, and consistent timing; with supplements, lower doses are often more sensible than higher ones.
Caffeine + L-Theanine can improve alertness, attention, and subjective “nervousness” under caffeine in studies, but the evidence is overall small to moderate and strongly dependent on dosage, task type, and caffeine amount. Sleep, caffeine timing, and total intake remain more important than the supplement itself.
HRV Biofeedback can reduce stress markers in studies and influence the autonomic nervous system, especially as a complementary method. The evidence is strongest for stress, anxiety, and some pain-related endpoints; for many other goals it remains limited. First optimize sleep, movement, light, and breathing, then Biofeedback.
Magnesium is an essential mineral, but the evidence for noticeable added benefits in healthy people is limited. Its best-supported use is correcting a deficiency; evidence for blood pressure, migraine, and cramps is only partial. Before supplements, sleep, diet, and identifying causes come first.
Vitamin optimization makes the most sense when a deficiency is present or the risk is high. For healthy people without a deficiency, the benefit of supplements is usually small or unproven. Priority should go to nutrition, sunlight, movement, and sleep; lab values and medical evaluation should come before high-dose products.
The three best-known sleep books emphasize different things: Walker explains sleep in a popular way, Foster frames chronobiology, and Littlehales provides practical guidance for everyday life and sport. For readers, the key point is that Walker’s mortality claims were publicly criticized; the most robust data concern sleep duration, regularity, and light.
The best-supported 30-minute morning routine starts with bright daylight, then short movement, fluids, and only later caffeine. Light stabilizes the body clock, movement increases alertness, and delaying caffeine may protect sleep. The evidence is strongest for light, while electrolytes and some timing details remain mixed.
In PCOS, Inositol — especially Myo-Inositol — may improve ovulation, hormone values, and some metabolic parameters according to meta-analyses. In direct comparison with Metformin, the effects are often similar, but the studies are heterogeneous and in some cases small. Lifestyle remains the foundation; data on safety and long-term benefit are still limited.
The well-known Kuopio cohort found, in observational data, lower cardiovascular and all-cause mortality with more frequent sauna use; 4–7 sessions per week performed better than 2–3. But this is not proof of causality. The studies mostly used 15–20 minutes at about 80–100 °C, with cooling breaks as tolerated.
Before supplements, prioritize sleep hygiene, morning light, movement, and enough fluids. For magnesium, the evidence for direct sleep effects is overall thin; the best data for magnesium are in people with low status. Glycine 3 g before bed has been studied in small RCTs with better subjective sleep quality and less daytime sleepiness, but the studies are small.
At biohacking conferences, targeted conversations with speakers, coaches, and industry contacts bring more value than random small talk. Clear goals, good preparation, short openings, active listening, and clean follow-up within 24 hours work best. Evidence on networking itself is mostly observational, not experimental.
Many free online summits are primarily marketing funnels with backend sales; they are only worthwhile in terms of content when they provide clear evidence, independent speakers, and transparent sponsors. Because screen time has been shown to worsen sleep quality, the practical value is often good only when you choose sessions deliberately and do not keep consuming until sleep suffers.
Longevity Day Munich shows one thing above all: German longevity research in 2026 is strong in basic science, biomarker, and prevention questions, but clinical endpoints are often still rare. For readers, sleep, movement, nutrition, and light come first; supplements and anti-aging interventions are usually much less well supported.
The Biohacker Summit Helsinki 2026 is especially relevant for DACH biohackers if they are looking for evidence-aligned talks, practical relevance, and a Scandinavian biohacking perspective. In this article, we classify speakers, topics, travel value, ticket questions, and the evidence hierarchy so you can separate marketing from reliable content.
The Health Optimisation Summit Berlin is especially worthwhile for readers looking for concrete contacts, new perspectives, and curated content; as a pure source of knowledge, the talks do not replace systematic evidence review. Its biggest value usually lies in networking, selected workshops, and orientation on which trends are actually supported by solid evidence.
Biohacking is not a catch-all term for miracle remedies, but a mix of measurement, lifestyle, and targeted interventions. If you understand the key terms such as HRV, ApoB, RCT, Zone 2, Cohen-d, NMN, and RED-S, you can classify studies better, spot marketing faster, and prioritize measures sensibly: sleep, movement, and nutrition before supplements.
Training, nutrition and recovery can be adapted to the female cycle, but the effects are usually small to moderate and highly individual. The most consistent pattern is: place harder sessions more often in the follicular phase, plan for a higher subjective load in the luteal phase, prioritize sleep and energy intake, and avoid overestimating the evidence.
In perimenopause, the strongest levers are not supplements, but strength training, sufficient protein, sleep, movement, and bone protection. For hormone replacement therapy, the key is individual assessment, especially with troublesome symptoms; the evidence from KEEPS and ELITE suggests a more favorable start in early menopause, not a blanket recommendation.
Ferritin is a storage-iron marker, and in women values below 50 ng/ml can be associated with fatigue, reduced performance, and hair loss even with normal Hb. Standard primary-care tests often miss early deficiencies; ferritin, blood count, and inflammatory markers are needed for interpretation. Iron should only be supplemented after diagnosis, because overdose and incorrect self-treatment carry risks.
Biohacking is mainly useful for healthy adults interested in sleep, movement, nutrition, and self-observation. You should not start, or should only do so with medical supervision, during pregnancy, with severe illness, a history of eating disorders, as a minor, or with risky experiments involving sleep, fasting, or stimulants. The benefit depends heavily on the method, goal, and evidence base.
Zone-2 cardio is usually the intensity just below the first lactate threshold, where you can still speak in full sentences. The 150–180 minutes per week range is a practical target, but it is not exactly proven. The best approach is talk test plus heart rate, not a single number.
Directly after strength training, Cold Plunge can blunt hypertrophy and strength adaptation if muscle gain is the goal; several RCTs and reviews show this. For competition season, tightly scheduled multiple sessions, or acute pain reduction, it can be useful, ideally not directly after the workout.
“Lifespan” is not a scam, but it is also not proof of an anti-aging program. The strongest evidence is for basic biology around NAD+ and sirtuins; for NMN in humans, the data are still small and short. Lifestyle levers remain more relevant than supplements, and Sinclair’s roles at Sirtris and InsideTracker make a critical reading necessary.
“Roar” is primarily intended for menstruating athletes, while “Next Level” is for women in perimenopause and menopause. The practical difference is less about “more biohacking” than about the hormonal phase, the nutritional recommendations, and the training focus. The evidence for many specific book claims is partly limited and not always directly supported by RCTs.
“Outlive” is not a supplement book, but a priority plan: first sleep, movement, nutrition, and strength, then blood markers such as ApoB and metabolic markers. Attia’s core point is to lower risk factors early, because prevention comes before symptom treatment. For Rapamycin and other longevity approaches, the human data are still limited.
Evidence-based biohacking separates interventions by study signal, effect size, and risk: sleep, movement, light, and nutrition first, then supplements only when the data are solid. Wellness trends often offer plausibility instead of proof. The key is controlled studies, reproducibility, and clear limits of the evidence.
Biohacking means deliberately changing sleep, movement, light, nutrition, or technology to improve health or performance. Quantified Self is first about measurement: collecting data, recognizing patterns, understanding behavior. The two fields overlap, but they are not the same.
Rapamycin extends lifespan in several mouse models, but hard endpoint data on longevity are still missing for healthy humans. The current human evidence consists mainly of reviews, one observational study, and off-label practice reports. The data remain insufficient for benefit, dose, and long-term safety in humans.
Statins lower circulating CoQ10, but that does not automatically imply a clinically relevant deficiency. The evidence for CoQ10 in statin myalgias is mixed; for heart failure there are RCTs such as Q-SYMBIO, but with important limitations in blinding and generalizability. Ubichinol is more bioavailable, but the clinical advantage is not clearly proven.
Curcumin is pharmacokinetically difficult: unchanged Curcumin is only poorly detectable in the blood after oral intake. Piperin can markedly increase bioavailability in a widely cited human study, but it also carries interaction risks. Formulations such as Meriva, Theracurmin, or BCM-95 improve absorption, yet clinical benefits are not always shown to be proportional to higher blood concentrations.
Magnesium threonate is biologically plausible because it is supposed to reach the blood-brain barrier better, but the human evidence is still thin. There are small RCTs with hints of better cognitive measures and sleep, but the benefit is not securely established. For sleep, sleep hygiene, light, and movement come first; among supplements, the evidence for magnesium overall is stronger than for threonate specifically.
Resveratrol is interesting in mouse and mechanistic studies, but for human longevity endpoints there is currently no convincing RCT evidence. The oft-cited sirtuin story comes mainly from preclinical data; in human studies, effects are small, inconsistent, or dependent on baseline status. Anyone aiming to optimize health should first address sleep, movement, nutrition, and light.
Lion’s Mane (Hericium erinaceus) has a plausible biological basis, but the human evidence for cognition is still weak: there are only small, short RCTs, while mechanisms such as NGF come mainly from cell and animal studies. For healthy adults, a clear cognitive benefit is not proven; much remains open on dose and safety.
HRV is most useful as a trend marker for recovery and stress, not as an exact health value. For biofeedback, resonant breathing at about 6 breaths per minute is well supported and can favorably influence HRV, blood pressure, and mood. Wearables like Oura or Whoop are better for longitudinal data than for absolute comparisons.
Vitamin K2 (especially MK-7) has shown small to moderate effects on bone markers and, in some trials, on bone density, particularly in postmenopausal women. For vascular or cardiovascular outcomes, the evidence is much weaker. The best foundation remains sleep, movement, nutrition, and adequate vitamin D; K2 is more of an add-on.
Ashwagandha shows moderate effects on stress, anxiety, and in some cases sleep quality in several randomized studies; for testosterone there are positive, but small and not universally generalizable RCTs. In practice: sleep, light, movement, and nutrition come first. Since 2023, Scandinavian liver safety warnings also deserve serious attention.
Cold immersion is not a miracle cure. For brown fat, there are signs of adaptation, but most data come from small human studies or animal models. For mood and recovery, the evidence is much thinner; robust effects, dose, and safety have not yet been clearly established.
Morning daylight is one of the most effective, lowest-cost interventions for the circadian rhythm: it shifts and stabilizes the internal clock, promotes evening melatonin release, and can improve daytime alertness in many people. The often-cited “1000 lux in the first hour” rule is practical, but the evidence is more complex than social-media shorthand suggests.
The Laukkanen studies are interesting observational data: more frequent sauna use was associated with lower all-cause, cardiovascular, and dementia mortality. But this does not prove causality, because lifestyle and health can also shape the results. RCTs are lacking; sauna is at most a plausible but unproven longevity lever.
L-Theanine plus caffeine is a sensible focus stack when sleep, light, and movement are already in place. In several RCTs, the combination improved attention and reaction time; a commonly used ratio is 1:2, for example 100 mg caffeine plus 200 mg L-Theanine. The evidence is moderate, not definitive.
Selenium can lower TPO antibodies in Hashimoto in several randomized studies, usually at 200 µg/day for 3–6 months. But the clinical benefit for symptoms is inconsistent. Before supplements, iodine status, sleep, nutrition, and thyroid medication matter more. Too much selenium can be harmful; high levels in the SELECT study signaled a higher diabetes risk.
Quercetin is a flavonoid with plausible effects on mast cells and allergic symptoms, but the clinical evidence is limited and often small. For hay fever, there are isolated positive but not robust studies; for exercise performance and antiviral effects, the data are mixed to limited. Bioavailability is a central problem.
NEAT is daily movement outside planned training and matters greatly for energy expenditure, health, and sedentary risk. Observational studies show: even more steps per day are associated with lower mortality, and in one large US analysis, about 4,400 steps/day was already more favorable than very low activity.
Creatine can improve strength performance in women; the evidence for bone density and cognition is much thinner and often context-dependent. The common dosage is broadly the same for women and men, usually 3–5 g daily. Water retention is possible, but it does not automatically mean fat gain or looking “puffy.”
Most randomized studies show: intermittent fasting is usually about as effective as classic calorie restriction for weight loss, but not clearly superior. For glucose, insulin, and other metabolic markers, the effects are small to moderate and strongly dependent on the comparison diet. Human evidence for autophagy remains thin; in women, menstrual disruption and overly aggressive fasting protocols should be taken seriously.
Breathing techniques can subjectively reduce stress, but the evidence varies widely by method. For Box Breathing and Buteyko, clinical data are limited; for the Wim Hof method, the endotoxin study by Kox et al. 2014 is important, but often overinterpreted. Hyperventilation carries real risks, including dizziness, fainting, and injury.
The biggest sleep-hygiene effects usually do not come from supplements, but from consistency: a fixed wake time, plenty of morning light, less bright light in the evening, a cool bedroom, caffeine early enough, and no alcohol as a sleep aid. The strength of the data varies by lever; the most robust evidence is for light, caffeine, and alcohol effects on sleep architecture, while some everyday rules are derived more from observations and mechanistic reasoning.
NMN, Nicotinamid-Ribosid (NR), and Nicotinamid can raise NAD+ markers in blood, but the clinical evidence for sleep, insulin sensitivity, or muscle function remains thin so far. The 2026 literature is clearly biomarker-heavy: good signals for NAD+ metabolites, but no robust data for hard endpoints, and the studies are heterogeneous in dose, duration, and population.
Semaglutide and Tirzepatide are among the most effective medications for weight loss; however, the long-term benefit depends heavily on whether treatment is continued and combined with nutrition, exercise, and sleep. After stopping, the risk of weight regain is relevant. Data on muscle mass loss are still limited, and lifestyle factors remain central to maintaining results.
Berberine can moderately lower blood sugar in people with type 2 diabetes and insulin resistance, but the data are heterogeneous and study quality is often limited. Reviews and meta-analyses usually show a small to medium effect on fasting blood glucose, HbA1c, and insulin resistance; direct comparisons with metformin exist, but they are short and methodologically limited. Priority should go to sleep, movement, weight loss, and diet; berberine is not a substitute for physician-managed therapy.